How I approach B‐lymphoblastic lymphoma in children

There are limited data pertaining to the prognostic features and optimal therapeutic approach for the 20%–25% of children with lymphoblastic lymphoma (LLy) who have the B‐lymphoblastic subtype. Outcomes are favorable following treatment modeled after acute lymphoblastic leukemia (ALL) regimens, but...

Full description

Saved in:

Bibliographic Details
Published in:	Pediatric blood & cancer Vol. 70; no. 8; pp. e30401 - n/a
Main Authors:	Devine, Kaitlin J., Fries, Carol, Hermiston, Michelle, Wistinghausen, Birte
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01-08-2023
Subjects:	Acute lymphoblastic leukemia B‐cell Clinical trials Hematology Lymphatic leukemia lymphoblastic lymphoma Lymphoma Oncology pediatric oncology Pediatrics pediatric oncology B-cell lymphoblastic lymphoma
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	There are limited data pertaining to the prognostic features and optimal therapeutic approach for the 20%–25% of children with lymphoblastic lymphoma (LLy) who have the B‐lymphoblastic subtype. Outcomes are favorable following treatment modeled after acute lymphoblastic leukemia (ALL) regimens, but prognosis is dismal after relapse, and there are no established features for predicting therapy response. Ongoing US and international trials will include the largest cohort of uniformly treated patients with B‐LLy to date, providing an opportunity to define clinical and molecular predictors of relapse and to establish a standard of care for treatment to improve outcomes for this rare pediatric cancer.
Bibliography:	Kaitlin J. Devine and Carol Fries contributed equally as co‐first authors. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1545-5009 1545-5017
DOI:	10.1002/pbc.30401